| Wissenschaftl. Titel | SUNRAY-01, A Global Pivotal Study in Participants with KRAS G12C-Mutant, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Comparing First- Line Treatment of LY3537982 and Pembrolizumab vs Placebo and Pembrolizumab in those with PD-L1 expression ≥50% or LY3537982 and Pembrolizumab, Pemetrexed, Platinum vs Placebo and Pembrolizumab, Pemetrexed, Platinum regardless of PD-L1 Expression |
| Erkrankung |
Thorax:
Nicht-kleinzelliges Lungenkarzinom:
Erstlinie
|
| Molekularer Marker |
KRASG12C |
| Kurzprotokoll | Kurzprotokoll |
| Links | Weiterführende Informationen (M, Gauting) Weiterführende Informationen (NIH) |
erstellt 16.05.2024 Data entry III CCP
geändert 13.06.2024 Data entry IX CCP